Telix Pharmaceuticals (TLX) Income Statement: Revenue & Earnings

Telix Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Telix Pharmaceuticals Limited income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	487.02	342.39	108.91	5.52	4.02
Cost of Revenue	170.09	128.19	44.34	1.85	1.56
Gross Profit	316.93	214.19	64.58	3.67	2.46
Operating Expenses
Research & Development	121.03	87.57	54.89	24.82	17.81
Selling, General & Administrative	144.80	91.40	59.47	34.16	18.88
Operating Expenses	266.28	178.86	115.05	62.75	40.46
Operating Income	50.65	35.34	-50.48	-59.08	-38.00
Other Income/Expense
Interest Income	6.75	0.69	0.00	0.00	0.05
Interest Expense	22.69	9.24	4.50	-0.12	-0.15
Other Income/Expense	0.42	-24.55	-12.06	10.25	9.34
Income
Income Before Tax	34.86	2.10	-67.09	-58.51	-36.98
Income Tax Expense	3.82	-1.45	3.71	0.03	-2.35
Net Income	31.04	3.55	-70.80	-58.54	-34.63
Net Income - Continuous Operations	31.04	3.55	-70.80	-58.36	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	57.55	11.34	-62.60	-55.79	-34.67
EBIT	57.55	11.34	-62.60	-59.08	-38.00
Depreciation & Amortization	3.52	6.74	3.66	3.29	3.33
Earnings Per Share
Basic EPS	-	-	-	-	-
Diluted EPS	-	-	-	-	-
Basic Shares Outstanding	331.23	319.18	310.64	282.21	257.27
Diluted Shares Outstanding	345.19	319.18	310.64	282.21	257.27